Metrics as of 10/15/2026, 12:55 PM (Berlin time), refresh in progress.
TransMedics Group Stock
TransMedics Group, Inc.
Company data
- Sector
- Healthcare
- Industry
- Medical - Devices
- Country
- United States
- CEO
- Waleed H. Hassanein
- Employees
- 898
- Market cap
- $2.6 B
- IPO
- 02/05/2019
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise within the Healthcare sector. Headquartered in Andover, the company was founded in 1998. The core of its business model is focused on transforming the landscape of organ transplant therapy for patients worldwide grappling with…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
TransMedics Group stock: price history
1D
-4.6%
1W
-6.8%
1M
-12.0%
6M
-35.0%
YTD
-37.9%
1Y
-32.1%
2Y
-43.7%
5Y
+184.4%
10Y
–
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~114% stronger price swings than usual
Ask the agents about TransMedics Group
Analyst assessment of TransMedics Group
PRICE TARGET LOW
US$65.00
CONSENSUS
US$99.63
MEDIAN
US$100.00
PRICE TARGET HIGH
US$122.00
0
STRONG BUY
9
BUY
4
HOLD
0
SELL
0
STRONG SELL
13
TOTAL · Buy
As of: 13/10/2026
TransMedics Group stock metrics
P/E
17.09
P/B
5.04
EV/EBITDA
23.14
RETURN ON EQUITY
2.8%
NET MARGIN
7.7%
DEBT/EQUITY
1.67
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
96.6%
FLOAT SHARES
33,507,286
AVG. DAILY VOLUME (30D)
757,457
Insider transactions (SEC)
Weill David
TOBIN JAMES R
Corcoran Nicholas
Hassanein Waleed H
Hernandez Gerardo
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -4.6%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about TransMedics Group stock
What does TransMedics Group do?
TransMedics Group, Inc. is a company in the Healthcare sector, Medical - Devices industry, headquartered in United States.
The CEO is Waleed H. Hassanein, the company employs around 898 people.
The IPO was on 02/05/2019; the stock trades on NASDAQ under the ticker TMDX.
What do analysts say about TransMedics Group stock?
13 analysts rate the stock, the consensus is Buy (as of 13/10/2026).
The average price target is US$99.63, ranging from US$65.00 to US$122.00, with a median of US$100.00.
This is an external assessment, not a statement by Market Jury.
When does TransMedics Group report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly 114% stronger than usual.
Does TransMedics Group pay a dividend?
No, TransMedics Group currently does not pay a dividend.
Which stocks are comparable to TransMedics Group?
Comparable stocks include Abbott Laboratories, Stryker, Boston Scientific, Edwards Lifesciences, DexCom, GE HealthCare Technologies, Zimmer Biomet Holdings and Align Technology.
How can I get TransMedics Group stock analyzed?
Clicking "Analyze stock" lets five strategies assess TransMedics Group against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.